Comparing digital gait and turning measures from a prescribed gait test in the clinic/laboratory versus the same test at home in people with Parkinson’s disease
Objective: We aim to compare the performance of the same prescribed walk test in the laboratory/clinic versus in the home. Background: With the advent of…Research Information Disclosure In The PPMI Study: Development Of A Disclosure Process
Objective: The Parkinson Progression Markers Initiative (PPMI) is a multinational, longitudinal observational study that collects clinical, imaging, biologic, and genetic data from participants with or…Identifying Subjects with Dopamine Transporter Deficit in a Population-based Recruitment Strategy: Kassel Data of Healthy Brain Ageing
Objective: To identify subjects with dopamine transporter (DaT) deficit being at high risk for prodromal PD. Background: Neurodegeneration and dopaminergic deficit in PD occur before the development…Rationale and Design of the Slowing Parkinson’s Early through Exercise Dosage – United Kingdom (Slow-SPEED-UK) Trial
Objective: Slow-SPEED-UK is a randomized controlled trial investigating the effects of an app-based exercise program on individuals at higher risk of Parkinson’s Disease (PD). Background:…The Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons with REM Sleep Behavior Disorder (RBD)
Objective: To explore the potential for an immunologically based intervention to slow evolution of symptoms in persons with prodromal or Stage 2b (Simuni et al.…Analgesic effect of electroacupuncture on Relieving pain in Parkinson’s disease and the mechanism based on rs-fMRI
Objective: To investigate whether electroacupuncture (EA) on the primary motor cortex could reduce pain in patients with PD and to explore the mechanism behind its…Effect of various mGlu2 and mGlu2/3 activators on parkinsonism: a sub-analysis in the MPTP-lesioned primate
Objective: To evaluate the effect of the metabotropic glutamate 2/3 (mGlu2/3) orthosteric activators (OAs) LY-354,740 and LY-404,039, as well as the effects of the metabotropic…TrkB modulator OT-003 reduces dopaminergic cell loss, mitochondrial stress, alpha-synuclein aggregation and motor dysfunction in Parkinson’s disease models.
Objective: To assess efficacy and potency of our proprietary lead compound OT-003, an orally bioavailable small molecule Tropomyosin receptor kinase B (TrkB) modulator, in preclinical…Effect of Tactile Cueing on Dual Task Performance in Parkinson’s Disease-A Systematic Review and Meta-Analysis
Objective: This systematic review and meta-analysis were performed to examine the effect of tactile cueing on dual task (DT) performance in adults with idiopathic Parkinson’s…Adherence and Persistence Among Patients with Parkinson’s Disease Initiating Istradefylline: 12-Month Follow-Up from US Real-World Data
Objective: To evaluate 12-month adherence and persistence and identify factors associated with persistence among Parkinson’s disease (PD) patients initiating istradefylline, the first non-dopaminergic adjunct targeting…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 181
- Next Page »